Target intelligence / Profile preview

Dynamin-like GTPase OPA1, mitochondrial (OPA1)

Target
OPA1
Molecular classification
Dynamin-related GTPase, Mitochondrial protein, Inner mitochondrial membrane protein, Other (due to its function as a membrane-remodeling GTPase)
01

Overview

OPA1 is a mitochondrial inner membrane GTPase essential for mitochondrial inner membrane fusion, maintenance of cristae structure, and the integrity of mitochondrial DNA. It exists in multiple splice isoforms, localizes to the inner mitochondrial membrane, and is required for normal mitochondrial dynamics and energy production. Dysfunction or mutation of OPA1 leads to mitochondrial disorganization and increased susceptibility to apoptosis, contributing to dominantly inherited optic neuropathy (DOA), various neurological syndromes, and other mitochondrial diseases. Therapeutic targeting of OPA1 mRNA with antisense oligonucleotides is under investigation as a strategy to increase functional OPA1 protein in disorders such as dominant optic atrophy[1][2][3][4][5][6][8].

Other names
Optic atrophy protein 1OPA1 mitochondrial dynamin-like GTPaseDynamin-like 120 kDa protein, Kjer type
02

Mechanism of action

Splice-switching antisense oligonucleotides decrease inclusion of poison exons in OPA1 mRNA, increasing production of functional OPA1 protein

03

Biological functions

Mitochondrial fusionRegulation of cristae morphologyMaintenance of mitochondrial DNA (mtDNA) integrityOxidative phosphorylationRegulation of apoptosis (cell death)
04

Disease associations

Neurodegenerative disease (notably optic neuropathy, e.g., dominant optic atrophy [DOA])CardiomyopathyAtaxiaSensorineural hearing lossMitochondrial diseaseParkinson's disease (possible association)
05

Safety considerations

Off-target effects of mRNA-targeting therapies (e.g., antisense oligonucleotides)Mitochondrial dysfunction or unintended acceleration of apoptosisVision or hearing loss progression (underlying disease manifestations)
06

Interacting drugs

Antisense oligonucleotides (e.g., STK-002, currently experimental)
07

Biomarkers

OPA1 protein levels (for patient selection or response monitoring in optic atrophy therapy)Mitochondrial morphology markers (for mitochondrial diseases)

Beyond the preview

Go deeper on Dynamin-like GTPase OPA1, mitochondrial (OPA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynamin-like GTPase OPA1, mitochondrial (OPA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call